Semaglutide vs Tirzepatide
Semaglutide and tirzepatide represent two generations of incretin-based therapies that have reshaped the treatment of type 2 diabetes and obesity. Semaglutide is a pure glucagon-like peptide-1 receptor agonist (GLP-1 RA), while tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist. Understanding their differences in mechanism, efficacy, and clinical profile is essential for informed therapeutic selection.
Mechanism of Action
Section titled “Mechanism of Action”Semaglutide: GLP-1 Only
Section titled “Semaglutide: GLP-1 Only”Semaglutide is a synthetic GLP-1 analogue with an amino acid sequence modified at positions 8 (Aib for Ala) and 34 (Arg for Lys), along with a C-18 fatty diacid chain attached via a linker to Lys26. The fatty acylation enables non-covalent albumin binding, extending the half-life to approximately 165 hours (7 days) — a dramatic improvement over native GLP-1’s 2–3 minute half-life.
Semaglutide binds the GLP-1 receptor (GLP-1R) with high affinity (EC₅₀ ~0.2 nM), activating the Gs-protein adenylyl cyclase–cAMP–PKA pathway. This triggers glucose-dependent insulin secretion from pancreatic β-cells, suppresses glucagon release from α-cells, slows gastric emptying, and acts on hypothalamic circuits to reduce appetite and food intake.
Tirzepatide: GLP-1/GIP Dual Agonism
Section titled “Tirzepatide: GLP-1/GIP Dual Agonism”Tirzepatide is a linear 39-amino acid peptide with a C-20 eicosanedioic acid moiety conjugated at Lys-20. It engages both GIPR and GLP-1R with potent dual agonism, though with differential receptor selectivity (EC₅₀ for GIPR ~0.14 nM vs. GLP-1R ~0.18 nM).
The GIP receptor component enhances adipose tissue lipid handling and augments GLP-1-mediated insulin secretion, while central GIPR activation synergizes with GLP-1R signaling for appetite suppression. Tirzepatide’s GIPR agonism is notably more potent than its GLP-1R activity — a pharmacological distinction from balanced dual agonists.
Receptor Binding Affinity
Section titled “Receptor Binding Affinity”| Property | Semaglutide | Tirzepatide |
|---|---|---|
| GLP-1R EC₅₀ | ~0.2 nM | ~0.18 nM |
| GIPR EC₅₀ | No agonism | ~0.14 nM |
| Albumin binding | High (C-18 diacid) | High (C-20 diacid) |
| Half-life | ~165 hrs (7 days) | ~116 hrs (5 days) |
The key pharmacological distinction is that tirzepatide activates two incretin receptors simultaneously. Native GIP has been considered relatively weak in its metabolic effects, but the combination with GLP-1R agonism produces synergistic benefits that neither receptor alone achieves.
Clinical Trial Evidence
Section titled “Clinical Trial Evidence”SURPASS Trials (Tirzepatide)
Section titled “SURPASS Trials (Tirzepatide)”The SURPASS program established tirzepatide’s superiority across glycemic and weight endpoints:
- SURPASS-1: Tirzepatide monotherapy vs. placebo in treatment-naïve patients. HbA1c reductions of 1.87–2.07% vs. 0.30% (placebo) at 40 weeks.
- SURPASS-2: Tirzepatide vs. semaglutide 1 mg in patients on metformin. Tirzepatide 5 mg, 10 mg, and 15 mg achieved HbA1c reductions of 2.09%, 2.37%, and 2.46%, respectively, versus 1.84% for semaglutide 1 mg. Weight loss: 7.6 kg, 9.6 kg, and 11.7 kg vs. 5.7 kg.
- SURPASS-3: Tirzepatide vs. insulin glargine. Superior HbA1c reduction and weight loss with all tirzepatide doses.
- SURPASS-4: Tirzepatide vs. insulin glargine in high-cardiovascular-risk patients. Demonstrated non-inferior cardiovascular safety.
STEP Trials (Semaglutide)
Section titled “STEP Trials (Semaglutide)”The STEP program evaluated semaglutide 2.4 mg weekly for obesity:
- STEP-1: Semaglutide 2.4 mg vs. placebo in non-diabetic obese adults. Mean weight loss 14.9% vs. 2.4% at 68 weeks. 86.4% of participants achieved ≥5% weight loss vs. 31.5%.
- STEP-2: Semaglutide 2.4 mg in obese patients with type 2 diabetes. Weight loss 9.6% vs. 3.4% (placebo). HbA1c reduction 1.6%.
- STEP-3: Semaglutide combined with intensive behavioral therapy. Weight loss 16.0% vs. 5.7%.
- STEP-4: Withdrawal study confirming sustained weight loss with continued treatment (17.4% loss) vs. regain after switch to placebo (5.6% loss).
Head-to-Head: SURPASS-2
Section titled “Head-to-Head: SURPASS-2”SURPASS-2 is the most direct comparison. Tirzepatide 10 mg and 15 mg achieved statistically superior HbA1c and weight reductions versus semaglutide 1 mg. However, semaglutide was dosed at 1 mg (the diabetes dose), not 2.4 mg (the obesity dose). This limits direct extrapolation to obesity treatment, where semaglutide 2.4 mg achieves substantially greater weight loss.
Dosing Regimens
Section titled “Dosing Regimens”| Parameter | Semaglutide (Ozempic) | Semaglutide (Wegovy) | Tirzepatide (Mounjaro) |
|---|---|---|---|
| Indication | Type 2 diabetes | Obesity | Type 2 diabetes |
| Starting dose | 0.25 mg weekly | 0.25 mg weekly | 2.5 mg weekly |
| Maintenance | 0.5–2 mg weekly | 2.4 mg weekly | 5–15 mg weekly |
| Titration | Every 4 weeks | Every 4 weeks | Every 4 weeks |
| Route | Subcutaneous | Subcutaneous | Subcutaneous |
Both agents use dose titration to mitigate gastrointestinal side effects. Semaglutide for obesity reaches a fixed maintenance dose of 2.4 mg, while tirzepatide allows dose escalation to 15 mg based on tolerability and glycemic response.
Side Effect Profiles
Section titled “Side Effect Profiles”The side effect profiles are broadly similar, reflecting shared GLP-1R-mediated effects on the gastrointestinal tract:
| Side Effect | Semaglutide | Tirzepatide |
|---|---|---|
| Nausea | 20–44% | 12–31% |
| Diarrhea | 12–30% | 12–17% |
| Vomiting | 8–24% | 5–12% |
| Decreased appetite | 15–26% | 11–18% |
| Constipation | 16–24% | 11–18% |
| Injection site reactions | 1–7% | 2–6% |
Tirzepatide generally shows lower rates of nausea and vomiting, which may relate to its dual-receptor pharmacology attenuating the GI-mediated effects of pure GLP-1R agonism. Both agents carry a boxed warning regarding thyroid C-cell tumors observed in rodent studies, though human relevance remains uncertain.
No pancreatitis signal has emerged in clinical trials for either agent, though both carry warnings. Gallbladder-related adverse events (primarily cholelithiasis) occur at low rates with rapid weight loss on either drug.
Weight Loss Efficacy
Section titled “Weight Loss Efficacy”Semaglutide 2.4 mg (STEP trials)
Section titled “Semaglutide 2.4 mg (STEP trials)”- Mean weight loss: 14.9% body weight at 68 weeks
- ≥10% weight loss: 69% of participants
- ≥15% weight loss: 50% of participants
- ≥20% weight loss: 32% of participants
Tirzepatide 15 mg (SURMOUNT-1)
Section titled “Tirzepatide 15 mg (SURMOUNT-1)”- Mean weight loss: 20.9% body weight at 72 weeks
- ≥10% weight loss: 85% of participants
- ≥15% weight loss: 73% of participants
- ≥20% weight loss: 56% of participants
Tirzepatide 15 mg achieves greater weight loss than semaglutide 2.4 mg in available comparisons. However, the SURMOUNT-1 trial used a tirzepatide dose (15 mg) not yet approved for obesity in all markets, and direct head-to-head trials at matched indications are limited.
HbA1c Reduction
Section titled “HbA1c Reduction”Semaglutide
Section titled “Semaglutide”- 0.5 mg: ~1.0% reduction
- 1.0 mg: ~1.5–1.8% reduction
- 2.0 mg: ~2.0% reduction
Tirzepatide
Section titled “Tirzepatide”- 5 mg: ~1.8–2.0% reduction
- 10 mg: ~2.2–2.4% reduction
- 15 mg: ~2.4–2.6% reduction
Tirzepatide achieves greater HbA1c reductions at all dose levels, likely reflecting additive GIPR-mediated insulin sensitization and secretion augmentation.
Cost and Availability
Section titled “Cost and Availability”| Factor | Semaglutide | Tirzepatide |
|---|---|---|
| Brand names | Ozempic (diabetes), Wegovy (obesity), Rybelsus (oral) | Mounjaro (diabetes), Zepbound (obesity) |
| List price (monthly) | ~$935–1,350 | ~$1,023–1,059 |
| Insurance coverage | More broadly covered for diabetes | Expanding coverage |
| Oral availability | Yes (Rybelsus, 3–14 mg) | No (injectable only) |
| Supply stability | Historically constrained | Increasingly available |
The oral semaglutide formulation (Rybelsus) offers a non-injectable option absent for tirzepatide, which may improve adherence for needle-averse patients.
When to Choose Which
Section titled “When to Choose Which”Semaglutide may be preferred when:
- Patient prefers oral administration
- Obesity is the primary indication (Wegovy has dedicated obesity data)
- Cost or insurance coverage favors semaglutide
- Simpler mechanism of action is desired
- Patient has failed prior GLP-1 RA and tolerates the class
Tirzepatide may be preferred when:
- Maximum glycemic control is the goal
- Greater weight loss is desired (particularly at higher doses)
- Patient has inadequate response to semaglutide or other GLP-1 RAs
- Dual incretin mechanism is of interest
- Cost and access are comparable
Comparison Table
Section titled “Comparison Table”| Feature | Semaglutide | Tirzepatide |
|---|---|---|
| Mechanism | GLP-1 RA | GIP/GLP-1 dual agonist |
| Half-life | ~165 hours | ~116 hours |
| Max HbA1c reduction | ~2.0% | ~2.6% |
| Max weight loss | ~15% body weight | ~21% body weight |
| Oral option | Yes | No |
| GI side effects | Moderate | Slightly lower |
| Dosing frequency | Once weekly | Once weekly |
| Primary indication | Diabetes + obesity | Diabetes + obesity |
References
Section titled “References”- Wilding JPH, et al. “Once-weekly semaglutide in adults with overweight or obesity (STEP 1).” NEJM 2021;384:989-1002.
- Frías JP, et al. “Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2).” NEJM 2023;388:523-534.
- Jastreboff AM, et al. “Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1).” NEJM 2022;387:205-216.
- Davies MJ, et al. “Semaglutide 2.4 mg once weekly in adults with overweight or obesity (STEP 2).” Lancet 2021;397:1003-1012.
- Rosenstock J, et al. “Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1).” Lancet 2021;398:143-155.